Merck announced the appointment of Rachel Stahler as Chief Information Officer for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.
Rachel will be responsible for all information technology strategy, infrastructure, operations and delivery for Organon, and will drive digital capabilities in support of the company’s innovation strategy. Rachel also comes from Allergan, where she recently served as Chief Information Officer (CIO). Rachel has expertise in a broad range of information technology disciplines with deep understanding of the development, manufacturing and commercialization processes, having held roles in all three domains. Prior to Allergan, Rachel held CIO positions in multiple global health care organizations, including Syneos Health / Inventiv Health and Optimer Pharmaceuticals.
According to Kenneth C. Frazier, chairman and chief executive officer, Merck, Rachel's "deep expertise and pharmaceutical industry knowledge" makes her an important addition to the team "at this pivotal moment in Organon’s preparation to become an independent company focused on positively impacting the lives of patients and improving public health.”
Rachel is a proven leader "who understands the complexities of a large global pharmaceutical business,” said Kevin Ali, appointed chief executive officer of Organon. Her experience, says Ali, "will be so critical to advancing Organon’s vision to be the world’s leading women’s health company.”